Neostem Inc., of New York, said it expanded manufacturing services under an existing services agreement between its wholly owned subsidiary, PCT, and Kite Pharma Inc., of Santa Monica, Calif., which is developing engineered autologous T cell therapy (eACT) products for the treatment of cancer.